rosiglitazone + pioglitazone + placebo

This is a combination regimen used in clinical trials comparing the effects of rosiglitazone, pioglitazone, and placebo. Rosiglitazone and pioglitazone are both thiazolidinediones (TZDs), a class of oral antidiabetic agents that act as peroxisome proliferator-activated receptor gamma (PPARγ) agonists to improve insulin sensitivity in peripheral tissues. Both drugs are indicated for the management of type 2 diabetes mellitus as adjuncts to diet and exercise, either alone or in combination with other antidiabetic medications. Placebo serves as an inactive control in these studies. The primary mechanism involves enhancing insulin sensitivity without directly stimulating insulin secretion, thereby lowering blood glucose levels[1][2][5]. Both agents have additional metabolic effects but differ somewhat in their impact on lipid profiles and cardiovascular risk[6][10].